Table 3 Theoretical coverage of 30-valent vaccine in relation to Group A Streptococcus-associated clinical syndromes
Pharyngeal GAS isolates, Auckland; n = 246 (95 % CI) | Skin GAS isolates, Auckland; n = 104 (95 % CI) | Pharyngeal GAS isolates, Dunedin; n = 103 (95 % CI) | |
|---|---|---|---|
Theoretical 30-valent coverage | 48.4 % (42.2 %–54.6 %) | 33.7 % (25.3 %–43.2 %) | 93.2 % (86.4 %–96.9 %) |
Theoretical additional coverage with cross-opsonic effect a | 69.5 % (63.4 %–74.9 %) | 54.8 % (45.2 %–64.0 %) | 95.1 % (88.9 %–98.2) |
Proportion of isolates belonging to emm types not tested for cross-opsonic effect a | 27.6 % (22.4 %–33.6 %) | 38.5 % (29.7 %–48.1 %) | 2.9 % (0.6 %–8.6 %) |